| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
N-Nitrosodicyclohexylamine targets the androgen receptor (AR), functioning as a competitive antagonist. It competitively binds to the androgen receptor to inhibit the action of 5α-dihydrotestosterone (DHT), the active metabolite of testosterone. NDCHA can also reduce AR protein levels. As an N-nitroso compound, it is recognized for its potential carcinogenicity and is used as a reference standard in nitrosamine contamination analysis. Its anti-androgenic activity makes it a tool for studying androgen signaling and endocrine disruption.
|
|---|---|
| ln Vitro |
In vitro, N-Nitrosodicyclohexylamine has anti-androgenic activity, competitively binding to the androgen receptor to inhibit 5α-dihydrotestosterone action and reducing AR protein levels. Its activity is assessed in cell-based assays measuring AR-mediated transcriptional activity using AR-responsive reporter gene constructs. The compound's effects on cell proliferation and AR target gene expression are evaluated in AR-positive prostate cancer cell lines. Its anti-androgenic activity makes it a tool for studying androgen signaling and endocrine disruption.
|
| ln Vivo |
Specific in vivo activity data for N-Nitrosodicyclohexylamine are not extensively documented in the publicly available literature. As a carcinogenic agent with anti-androgenic activity, the compound has been studied in toxicology and carcinogenicity studies. It is recognized for its potential carcinogenicity and requires careful handling under controlled laboratory conditions. Its anti-androgenic effects may also be evaluated in vivo in models of endocrine disruption. Further studies are needed to fully characterize its in vivo effects.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for N-Nitrosodicyclohexylamine typically involve competitive binding experiments using androgen receptor and radiolabeled or fluorescently labeled androgen as tracer. The compound's binding affinity to AR is assessed, with IC₅₀ values determined through dose-response binding experiments. Assays are conducted in buffered solutions at physiological pH with appropriate receptor preparations. Its antagonist activity is confirmed through functional assays measuring AR-mediated transcriptional inhibition using AR-responsive reporter gene constructs.
|
| Cell Assay |
In vitro cell-based assays for N-Nitrosodicyclohexylamine utilize AR-positive cell lines to assess its anti-androgenic activity. Cells are treated with varying concentrations of the compound for 24-72 hours. AR-mediated transcriptional activity is evaluated using reporter gene assays with androgen response element (ARE)-luciferase constructs. Cell proliferation is assessed using MTT or CCK-8 assays. AR protein levels are measured by Western blot. Standard cell culture conditions (37°C, 5% CO₂) with charcoal-stripped serum are employed.
|
| Animal Protocol |
In vivo animal studies with N-Nitrosodicyclohexylamine are typically conducted in toxicology and carcinogenicity studies. The compound is administered to rodents via oral or other routes to evaluate its carcinogenic potential and anti-androgenic effects. Endpoints include assessment of tumor incidence, measurement of androgen-sensitive parameters, evaluation of reproductive toxicity, and histopathological analysis. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
N-Nitrosodicyclohexylamine has a molecular weight of 210.32 g/mol and a molecular formula of C₁₂H₂₂N₂O. It appears as a pale yellow to orange oily liquid. The compound is used as a reference standard in nitrosamine contamination analysis. It is recognized for its potential carcinogenicity and requires careful handling under controlled laboratory conditions. The compound is typically stored under conditions recommended for analytical reference standards.
|
| Toxicity/Toxicokinetics |
N-Nitrosodicyclohexylamine is a known carcinogenic agent and requires careful handling under controlled laboratory conditions. As an analytical reference standard, it is used in trace quantities in quality control testing and does not present significant toxicological concerns at these levels when proper safety precautions are followed. Standard laboratory safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment and proper waste disposal procedures. The compound should be handled in well-ventilated areas.
|
| References | |
| Additional Infomation |
N-Nitrosodicyclohexylamine (NDCHA) (CAS#: 947-92-2) has a molecular formula of C₁₂H₂₂N₂O and a molecular weight of 210.32 g/mol. It is an N-nitroso compound with anti-androgenic activity, competitively binding to AR to inhibit 5α-dihydrotestosterone action and reducing AR protein levels. NDCHA is a carcinogenic agent and a novel anti-androgenic compound. It is used as a reference standard in nitrosamine contamination analysis. This compound is not a drug and is strictly a research and analytical reagent.
|
| Molecular Formula |
C12H22N2O
|
|---|---|
| Molecular Weight |
210.32
|
| Exact Mass |
210.173
|
| CAS # |
947-92-2
|
| PubChem CID |
13697
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.15g/cm3
|
| Boiling Point |
352.9ºC at 760mmHg
|
| Melting Point |
95-97ºC
|
| Flash Point |
167.3ºC
|
| Index of Refraction |
1.582
|
| LogP |
3.635
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC(CC1)N(C2CCCCC2)N=O
|
| InChi Key |
CYMNKXLBEMEABS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H22N2O/c15-13-14(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h11-12H,1-10H2
|
| Chemical Name |
N,N-dicyclohexylnitrous amide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7547 mL | 23.7733 mL | 47.5466 mL | |
| 5 mM | 0.9509 mL | 4.7547 mL | 9.5093 mL | |
| 10 mM | 0.4755 mL | 2.3773 mL | 4.7547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
